Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981556404> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2981556404 abstract "Abstract Background A decline of estimated glomerular filtration rate (eGFR) has been described in atrial fibrillation (AF) patients on Vitamin K antagonists (VKAs). Few real-world data on the modifications of eGFR in AF patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) do exist. Purpose To evaluate changes of renal function in AF patients treated with VKAs or NOACs. Methods Multicentre prospective cohort study including 1,667 patients with non-valvular AF from 5 clinical centres of Internal Medicine and Cardiology in Italy. Renal endpoints were: 1) median annual decline of eGFR; 2) transition to eGFR <50 ml/min/1.73 m2; 3) eGFR class worsening according to KDIGO 2012 classification. The eGFR was assessed by the CKD-EPI formula at baseline and during follow-up. Results Median age was 73.7±9.1 years and 43.3% were women. 743 patients were on VKAs and 924 on NOACs (Dabigatran, Rivaroxaban e Apixaban). Median annual eGFR decline was −2,11 (Interquartile Range [IQR] −5,68/−0,62] in patients on VKAs, −0,27 [IQR −9,00/4,54] with Dabigatran (p<0.001 vs. VKAs), −1,21 [IQR −9,98/4,02] with Rivaroxaban (p=0.004 vs. VKAs) and −1,32 [IQR −8,7/3,99] with Apixaban (p=0.003, vs. VKAs). Use of Dabigatran and Apixaban was associated to a lower transition to eGFR <50 mL/min/1.73 m2, compared to VKAs: adjusted Odds Ratio (aOR) 0.492, 95% Confidence Interval (CI) 0.298–0.813, p=0.006 for Dabigatran; aOR 0.449, 95% CI 0.276–0.728, p=0.001 for Apixaban). Regarding the eGFR class worsening, Dabigatran (aOR 0.70, 95% CI 0.503–0.975, p=0.035), Rivaroxaban (aOR 0.591, 95% CI 0.423–0.825, p=0.002), and Apixaban (aOR 0.591, 95% CI 0.429–0.815, p=0.001) were all associated to a lower rate of eGFR class worsening compared to VKAs. Forest plot Conclusions In this prospective multicentre cohort study, NOACs use was associated with a lower decline of renal function compared to VKAs. Patients on Dabigatran showed the lowest annual rate of eGFR decline and those on Apixaban and Rivaroxaban a lower eGFR class worsening. Acknowledgement/Funding None" @default.
- W2981556404 created "2019-11-01" @default.
- W2981556404 creator A5006406707 @default.
- W2981556404 creator A5014040319 @default.
- W2981556404 creator A5015795674 @default.
- W2981556404 creator A5041027462 @default.
- W2981556404 creator A5050407708 @default.
- W2981556404 creator A5070057174 @default.
- W2981556404 creator A5072316630 @default.
- W2981556404 creator A5076547685 @default.
- W2981556404 creator A5081019858 @default.
- W2981556404 creator A5081721648 @default.
- W2981556404 date "2019-10-01" @default.
- W2981556404 modified "2023-09-25" @default.
- W2981556404 title "P3472Modifications of renal function in atrial fibrillation patients treated with different oral anticoagulants: a multicentre cohort study" @default.
- W2981556404 doi "https://doi.org/10.1093/eurheartj/ehz745.0344" @default.
- W2981556404 hasPublicationYear "2019" @default.
- W2981556404 type Work @default.
- W2981556404 sameAs 2981556404 @default.
- W2981556404 citedByCount "0" @default.
- W2981556404 crossrefType "journal-article" @default.
- W2981556404 hasAuthorship W2981556404A5006406707 @default.
- W2981556404 hasAuthorship W2981556404A5014040319 @default.
- W2981556404 hasAuthorship W2981556404A5015795674 @default.
- W2981556404 hasAuthorship W2981556404A5041027462 @default.
- W2981556404 hasAuthorship W2981556404A5050407708 @default.
- W2981556404 hasAuthorship W2981556404A5070057174 @default.
- W2981556404 hasAuthorship W2981556404A5072316630 @default.
- W2981556404 hasAuthorship W2981556404A5076547685 @default.
- W2981556404 hasAuthorship W2981556404A5081019858 @default.
- W2981556404 hasAuthorship W2981556404A5081721648 @default.
- W2981556404 hasConcept C119060515 @default.
- W2981556404 hasConcept C126322002 @default.
- W2981556404 hasConcept C156957248 @default.
- W2981556404 hasConcept C159641895 @default.
- W2981556404 hasConcept C164705383 @default.
- W2981556404 hasConcept C2776301958 @default.
- W2981556404 hasConcept C2776704044 @default.
- W2981556404 hasConcept C2778661090 @default.
- W2981556404 hasConcept C2778810321 @default.
- W2981556404 hasConcept C2779161974 @default.
- W2981556404 hasConcept C2780638905 @default.
- W2981556404 hasConcept C71924100 @default.
- W2981556404 hasConceptScore W2981556404C119060515 @default.
- W2981556404 hasConceptScore W2981556404C126322002 @default.
- W2981556404 hasConceptScore W2981556404C156957248 @default.
- W2981556404 hasConceptScore W2981556404C159641895 @default.
- W2981556404 hasConceptScore W2981556404C164705383 @default.
- W2981556404 hasConceptScore W2981556404C2776301958 @default.
- W2981556404 hasConceptScore W2981556404C2776704044 @default.
- W2981556404 hasConceptScore W2981556404C2778661090 @default.
- W2981556404 hasConceptScore W2981556404C2778810321 @default.
- W2981556404 hasConceptScore W2981556404C2779161974 @default.
- W2981556404 hasConceptScore W2981556404C2780638905 @default.
- W2981556404 hasConceptScore W2981556404C71924100 @default.
- W2981556404 hasLocation W29815564041 @default.
- W2981556404 hasOpenAccess W2981556404 @default.
- W2981556404 hasPrimaryLocation W29815564041 @default.
- W2981556404 hasRelatedWork W11633418 @default.
- W2981556404 hasRelatedWork W19155525 @default.
- W2981556404 hasRelatedWork W3370658 @default.
- W2981556404 hasRelatedWork W3388698 @default.
- W2981556404 hasRelatedWork W5696161 @default.
- W2981556404 hasRelatedWork W5832825 @default.
- W2981556404 hasRelatedWork W6071 @default.
- W2981556404 hasRelatedWork W6668650 @default.
- W2981556404 hasRelatedWork W12952029 @default.
- W2981556404 hasRelatedWork W1651283 @default.
- W2981556404 isParatext "false" @default.
- W2981556404 isRetracted "false" @default.
- W2981556404 magId "2981556404" @default.
- W2981556404 workType "article" @default.